(12) Patent Application Publication (10) Pub. No.: US 2013/0164376 A1 BHAT Et Al
Total Page：16
File Type：pdf, Size：1020Kb
US 2013 0164376A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0164376 A1 BHAT et al. (43) Pub. Date: Jun. 27, 2013 (54) FORMULATIONS OF (+)-2-1-(3-ETHOXY-4- Publication Classification METHOXY-PHENYL)-2-METHANESULFO NYL-ETHYL-4-ACETYLAMINOISOINDO (51) Int. Cl. LINE-1,3-DIONE A613 L/4035 (2006.01) (52) U.S. Cl. (71) Applicant: Celgene Corporation, Summit, NJ (US) CPC .................................. A61K 31/4035 (2013.01) USPC ............................ 424/465: 514/417; 424/400 (72) Inventors: Sreenivas S. BHAT, Kendall Park, NJ (US); Michael T. Kelly, Lake Hopatcong, NJ (US) (57) ABSTRACT (73) Assignee: Celgene Corporation, Summit, NJ (US) Pharmaceutical compositions and single unit dosage forms of (21) Appl. No.: 13/727,366 (+)-2-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl (22) Filed: Dec. 26, 2012 ethyl-4-acetylaminoisoindoline-1,3-dione, or a pharmaceu tically acceptable stereoisomer, prodrug, salt, Solvate, Related U.S. Application Data hydrate, or clathrate thereof, are provided herein. Also pro (60) Provisional application No. 61/580,626, filed on Dec. vided are methods of treating, managing, or preventing vari 27, 2011. ous diseases or disorders. US 2013/0164376 A1 Jun. 27, 2013 FORMULATIONS OF (+)-2-1-(3-ETHOXY-4- ods of treating, managing, or preventing diseases and condi METHOXY-PHENYL)-2-METHANESULFO tions such as, but not limited to, cancer, pain, Macular Degen NYL-ETHYL-4-ACETYLAMINOISOINDO eration, a skin disease, a pulmonary disorder, an asbestos LINE-1,3-DIONE related disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis, a sleep CROSS REFERENCE TO RELATED disorder, hemoglobinopathy, anemia, an inflammatory dis APPLICATIONS ease, an autoimmune disease, a viral disease, a genetic dis 0001. This application claims the benefit of priority to ease, an allergic disease, a bacterial disease, an ocular neovas cular disease, a choroidal neovascular disease, a retina U.S. Provisional Patent Application Ser. No. 61/580,626, neovascular disease, and rubeosis, using Compound A, or a filed Dec. 27, 2011, the disclosure of which is incorporated by pharmaceutically acceptable stereoisomer, prodrug, salt, Sol reference herein in its entirety. Vate, hydrate, or clathrate thereof, in the dosage forms 1 FIELD described herein. 0002 Provided herein are formulations and dosage forms 4. DETAILED DESCRIPTION of (+)-2-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfo nyl-ethyl-4-acetylaminoisoindoline-1,3-dione. Methods of 4.1 Definitions using the formulations and dosage forms are also provided 0007 As used herein, the term “Compound A’ refers to herein. enantiomerically pure 2-1-(3-ethoxy-4-methoxy-phenyl)-2- 2. BACKGROUND methanesulfonyl-ethyl-4-acetylaminoisoindoline-1,3-di one. Without being limited by theory, Compound A is 0003 Drug substances are usually administered as part of believed to be (+)-2-1-(3-ethoxy-4-methoxy-phenyl)-2- a formulation in combination with one or more other agents methanesulfonyl-ethyl-4-acetylaminoisoindoline-1,3-di that serve varied and specialized pharmaceutical functions. one, which has the following structure: Dosage forms of various types may be made through selective use of pharmaceutical excipients. As pharmaceutical excipi ents have various functions and contribute to the pharmaceu Compound A tical formulations in many different ways, e.g., solubilization, dilution, thickening, stabilization, preservation, coloring, fla O Voring, etc. The properties that are commonly considered when formulating an active drug Substance include bioavail ability, ease of manufacture, ease of administration, and sta O O bility of the dosage form. Due to the varying properties of the active drug Substance to be formulated, dosage forms typi N O cally require pharmaceutical excipients that are uniquely tai lored to the active drug Substance in order to achieve advan / tageous physical and pharmaceutical properties. /\ 0004 (+)-2-1-(3-ethoxy-4-methoxy-phenyl)-2-meth anesulfonyl-ethyl-4-acetylaminoisoindoline-1,3-dione N" O O (“Compound A') is a compound with anti-inflammatory O activity in clinical development for the treatment of a variety of chronic inflammatory conditions. Pharmacologically, 0008. As used herein and unless otherwise indicated, a Compound A blocks the degradation of cyclic adenosine composition that is “substantially free” of a compound means monophosphate (cAMP) via inhibition of the phosphodi that the composition contains less than about 20 percent by esterase type IV (PDE4) enzyme, resulting in an increase in weight, more preferably less than about 10 percent by weight, cAMP in PDE4-expressing cells including monocytes, T even more preferably less than about 5 percent by weight, and cells, and neutrophils. Enzyme assay data using purified most preferably less than about 3 percent by weight of the PDE4 enzyme from U937 human monocytic cells indicate compound. that Compound A has a PDE4 ICs of about 74 nM. Com 0009. As used herein and unless otherwise indicated, the pound A and methods for its synthesis are described, e.g., in term "stereomerically pure’ means a composition that com U.S. Pat. No. 6,962,940, the disclosure of which is hereby prises one stereoisomer of a compound and is substantially incorporated by reference in its entirety. free of other stereoisomers of that compound. For example, a 0005. Due to its diversified pharmacological properties, Stereomerically pure composition of a compound having one Compound A is useful in treating, preventing, and/or manag chiral center will be substantially free of the opposite enan ing various diseases or disorders. Thus, a need exists as to tiomer of the compound. A stereomerically pure composition dosage forms of Compound Ahaving advantageous physical of a compound having two chiral centers will be substantially and pharmaceutical properties. free of other diastereomers of the compound. A typical ste reomerically pure compound comprises greater than about 80 3. SUMMARY percent by weight of one stereoisomer of the compound and 0006 Provided herein are pharmaceutical dosage forms of less than about 20 percent by weight of other stereoisomers of (+)-2-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl the compound, more preferably greater than about 90 percent ethyl-4-acetylaminoisoindoline-1,3-dione (“Compound by weight of one stereoisomer of the compound and less than A”), or a pharmaceutically acceptable prodrug, salt, Solvate, about 10 percent by weight of the other stereoisomers of the hydrate, or clathrate thereof. Also provided herein are meth compound, even more preferably greater than about 95 per US 2013/0164376 A1 Jun. 27, 2013 cent by weight of one stereoisomer of the compound and less ethylenediamines, aminoacids, hydroxyalkylamines, hetero than about 5 percent by weight of the other stereoisomers of cyclic and heteroaromatic amines, and polyether amines. the compound, and most preferably greater than about 97 0015. As used herein and unless otherwise indicated, the percent by weight of one stereoisomer of the compound and term “biohydrolyzable ester” means an ester of a compound less than about 3 percent by weight of the other stereoisomers that either: 1) does not interfere with the biological activity of of the compound. the compound but can confer upon that compound advanta 0010. As used herein and unless otherwise indicated, the geous properties in Vivo, Such as uptake, duration of action, or term “enantiomerically pure’ means a stereomerically pure onset of action; or 2) is biologically inactive but is converted composition of a compound having one chiral center. in vivo to the biologically active compound. Examples of 0011. As used herein, unless otherwise specified, the term biohydrolyzable esters include, but are not limited to, lower “pharmaceutically acceptable salt(s)' includes, but is not lim alkyl esters, alkoxyacyloxy esters, alkyl acylamino alkyl ited to, salts of acidic or basic moieties of a compound pro esters, and choline esters. vided herein. Basic moieties are capable of forming a wide 0016. As used herein and unless otherwise indicated, the variety of salts with various inorganic and organic acids. The term “biohydrolyzable amide' means an amide of a com acids that can be used to prepare pharmaceutically acceptable pound that either: 1) does not interfere with the biological acid addition salts of Such basic compounds are those that activity of the compound but can confer upon that compound form non-toxic acid addition salts, i.e., salts containing phar advantageous properties in Vivo, Such as uptake, duration of macologically acceptable anions. Suitable organic acids action, or onset of action; or 2) is biologically inactive but is include, but are not limited to, maleic, fumaric, benzoic, converted in vivo to the biologically active compound. ascorbic. Succinic, acetic, formic, oxalic, propionic, tartaric, Examples of biohydrolyzable amides include, but are not salicylic, citric, gluconic, lactic, mandelic, cinnamic, oleic, limited to, lower alkyl amides, C.-amino acid amides, tannic, aspartic, Stearic, palmitic, glycolic, glutamic, glu alkoxyacyl amides, and alkylaminoalkylcarbonyl amides. conic, glucaronic, saccharic, isonicotinic, methanesulfonic, 0017. As used herein, and unless otherwise specified, the ethanesulfonic, p-toluenesulfonic, benzenesulfonic acids, or terms “treat,” “treating” and “treatment contemplate an pamoic (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate) action that occurs while a patient is Suffering